Spectricity raises €14m in Series B round
Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
Entries by Thomas Gabrielczyk
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Vaccine development – strategic approach
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Byondis and Glycotope merge platforms to target carbohydrates
Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises €1.9bn European Life Sciences Fund
AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
BioNTech takes over cancer immunotherapy platform
Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Nanosyrinx raises £6.2m to validate drug delivery platform
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.